C4 Therapeutics, Inc. (CCCC) - Q1 2026 Filing Summary
Business Context and Reporting Period
This summary covers the Quarterly Report on Form 10-Q for C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, for the period ended March 31, 2026. The company focuses on targeted protein degradation (TPD) using its proprietary TORPEDO platform. Its lead product candidate, cemsidomide, is in Phase 2 development for multiple myeloma, while CFT8919 is in Phase 1 for non-small cell lung cancer (NSCLC) in collaboration with Betta Pharma.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $6,152 | $7,238 |
| Net Loss | $(25,129) | $(26,322) |
| Net Loss Per Share (Basic & Diluted) | $(0.20) | $(0.37) |
| Operating Expenses | $33,937 | $36,402 |
| Cash, Cash Equivalents & Marketable Securities | $268,300 | $296,830 |
| Accumulated Deficit | $(763,822) | $(660,021) |
Note: Revenue is derived entirely from collaboration agreements; the company has no product sales revenue.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by approximately $1.1 million (15%) compared to Q1 2025. This was primarily driven by a $1.4 million decrease in revenue from the MKDG collaboration (due to prioritizing one KRAS project) and the termination of the Merck collaboration in late 2025. These decreases were partially offset by a $2.0 million milestone achievement from Biogen.
- Expense Reduction: Total operating expenses decreased by $2.5 million. Research and Development (R&D) expenses fell by $2.5 million, largely due to reduced preclinical development costs following the Merck termination and lower stock-based compensation. General and Administrative (G&A) expenses remained flat.
- Liquidity Position: Cash and marketable securities decreased by approximately $28.5 million quarter-over-quarter, reflecting net cash used in operating activities of $29.9 million, partially offset by net cash provided by investing activities of $16.2 million (sales of marketable securities).
Guidance, Outlook, and Risks
- Clinical Progress: The company advanced cemsidomide into the Phase 2 MOMENTUM trial (first patient dosed February 2026) and the Phase 1b trial with elranatamab (first patient dosed March 2026). A new Phase 1b trial is planned for the first half of 2027.
- Capital Resources: Management expects current cash, cash equivalents, and marketable securities ($268.3 million) to fund operations for at least the next 12 months. The company anticipates needing substantial additional financing to complete development and commercialization.
- Recent Financing: In October 2025, the company completed an underwritten offering raising approximately $116.9 million in net proceeds, including the issuance of Class A and Class B warrants. No sales were made under the 2025 ATM program in Q1 2026.
- Subsequent Event: On April 8, 2026, C4 entered into a new collaboration with Roche (2026 Roche Agreement) for DACs, receiving a $20.0 million upfront payment with potential milestones exceeding $1.0 billion.
- Risks: Key risks include the unproven nature of the TPD platform, reliance on third-party manufacturers and collaborators, potential failure of clinical trials, and the need for future capital raises which may result in dilution.
Investor Verification Checklist
- Verify the timeline and enrollment status of the Phase 2 MOMENTUM trial for cemsidomide.
- Confirm the terms and potential dilution impact of the outstanding Class A and Class B warrants (approx. 101 million shares total) issued in the October 2025 offering.
- Monitor the cash burn rate relative to the stated 12-month liquidity runway, especially given the $29.9 million quarterly operating cash outflow.
- Review the details of the new April 2026 Roche agreement to understand the scope of the $20 million upfront and future milestone triggers.
- Assess the impact of the terminated Merck collaboration on the overall pipeline strategy and R&D cost structure.